TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection
Brief Summary: The AIR-BX1 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.


Options:
A: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
B: Arm Label: AZD9668 active treatment; Type: EXPERIMENTAL; Interventions: Drug: AZD9668 | Arm Label: AZD9668 placebo treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AZD9668; Assigned to Arm(s): AZD9668 active treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AZD9668 placebo treatment
C: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
D: Arm Label: Mannitol; Type: EXPERIMENTAL; Interventions: Drug: Inhaled mannitol | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched control | Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): Mannitol | Intervention Type: DRUG; Name: Matched control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection
Brief Summary: The AIR-BX1 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
B: Arm Label: Ciprofloxacin Inhale (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro, BAYQ3939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro, BAYQ3939); Assigned to Arm(s): Ciprofloxacin Inhale (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
D: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection
Brief Summary: The AIR-BX1 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a 28-day off-drug period. Following the two blinded courses, all participants received a 28-day course of open-label AZLI then were followed for an additional 56 days.


Options:
A: Arm Label: Ciprofloxacin dispersion for inhalation; Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin dispersion for inhalation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin dispersion for inhalation; Assigned to Arm(s): Ciprofloxacin dispersion for inhalation | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
C: Arm Label: AZLI-AZLI; Type: EXPERIMENTAL; Interventions: Drug: AZLI | Arm Label: Placebo-AZLI; Type: PLACEBO_COMPARATOR; Interventions: Drug: AZLI, Drug: Placebo | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI-AZLI, Placebo-AZLI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo-AZLI
D: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (BAYQ3939) dry powder for inhalation | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Ciprofloxacin (BAYQ3939) dry powder for inhalation; Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 28 Days on/off (Placebo 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease
Brief Summary: The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.


Options:
A: Arm Label: Tiotropium Respimat 5mcg (Tio R5); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Tiotropium Respimat 10mcg (Tio R10); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Tiotropium Inhalation Solution; Assigned to Arm(s): Tiotropium Respimat 10mcg (Tio R10), Tiotropium Respimat 5mcg (Tio R5) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Cognitive Behavioral Therapy (CBT-I); Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia | Arm Label: CBT-I + COPD-ED; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia, Behavioral: COPD Education | Arm Label: COPD Education (COPD-ED); Type: EXPERIMENTAL; Interventions: Behavioral: COPD Education | Arm Label: Attention Control (AC); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Insomnia; Assigned to Arm(s): CBT-I + COPD-ED, Cognitive Behavioral Therapy (CBT-I) | Intervention Type: BEHAVIORAL; Name: COPD Education; Assigned to Arm(s): CBT-I + COPD-ED, COPD Education (COPD-ED) | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention Control (AC)
D: Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Device: CHROMED monitoring system | Intervention Type: DEVICE; Name: CHROMED monitoring system; Assigned to Arm(s): Interventional

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease
Brief Summary: The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.


Options:
A: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
D: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease
Brief Summary: The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.


Options:
A: Intervention Type: DRUG; Name: Fluticasone 500mcg BD via accuhaler or identical placebo; Assigned to Arm(s): N/A
B: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
D: Arm Label: Fluticasone Furoate Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: FF Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: Fluticasone Furoate/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Pwdr, Fluticasone Furoate Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Pwdr, Fluticasone Furoate/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease
Brief Summary: The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID
C: Arm Label: Inhaled corticosteroid, Then placebo; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Arm Label: Placebo control, Then inhaled corticosteroid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Inhaled corticosteroid, Then placebo, Placebo control, Then inhaled corticosteroid
D: Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate/vilanterol | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate | Arm Label: vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: fluticasone furoate/vilanterol; Assigned to Arm(s): fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: fluticasone furoate; Assigned to Arm(s): fluticasone furoate | Intervention Type: DRUG; Name: vilanterol; Assigned to Arm(s): vilanterol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 4-week Multicentre, Randomized, Open Label, Parallel Group, Active Control Phase IV Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone in Comparison With Oxycontin in Korean Patients With Cancer Pain(TOP)
Brief Summary: Objectives:

To prove non-inferiority of Targin compared to Oxycontin in terms of change of pain intensity

1. Primary objective: Change of pain intensity (NRS 0-10) score (average pain over 24 hours obtained each evening) within 4 weeks
2. Secondary objectives: Bowel Habit (worsening/no change/improving), Total dose and frequency of rescue medication, Quality of Life (QOL; EORTC QLQ-C30), Duration to need of laxative use and Adverse events


Options:
A: Arm Label: 'Oxycodone/Naloxone'; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone/Naloxone | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone(single compound) | Intervention Type: DRUG; Name: Oxycodone/Naloxone; Assigned to Arm(s): 'Oxycodone/Naloxone' | Intervention Type: DRUG; Name: Oxycodone(single compound); Assigned to Arm(s): Oxycodone
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 2
C: Arm Label: Methylnaltrexone bromide; Type: EXPERIMENTAL; Interventions: Drug: Methylnaltrexone bromide | Intervention Type: DRUG; Name: Methylnaltrexone bromide; Assigned to Arm(s): Methylnaltrexone bromide
D: Arm Label: Morphine Sulphate; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Fentanyl; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Oxycodone; Type: N/A; Interventions: Drug: methylnaltrexone | Intervention Type: DRUG; Name: methylnaltrexone; Assigned to Arm(s): Fentanyl, Morphine Sulphate, Oxycodone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Intraoperative myocardial and pulmonary protection is important for better outcome after cardiac surgery. Ischemic preconditioning is one of organ protective strategies against ischemia-reperfusion injury by applying brief ischemia to the target organ before a subsequent critical ischemia, and its effect has been confirmed. However, its clinical application is not easy because ischemic insult may aggravate the function of vulnerable organ.

On the other hand, remote ischemic preconditioning (RIPC) is another protective approach by applying ischemia to other less vulnerable organ such as skeletal muscle before critical ischemia-reperfusion injury to heart. The effect of RIPC has been well demonstrated in adults and children. However, Little is known about the effect of remote ischemic precondition on the pediatric myocardium to ischemia and reperfusion injury. The effect of RIPC on the children remains to be further evaluated because the degree of ischemia-reperfusion injury is different according to age, cardiac pathology and cyanosis. In addition, the previous report on children dealt with a diverse range of congenital heart defects with a wide age range. The purpose of this study was to evaluate the effect of RIPC on myocardial and pulmonary protection in infants with pulmonary hypertension who need repair of simple ventricular septal defect.


Options:
A: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Other: remote ischemic preconditioning (RIPC) | Intervention Type: OTHER; Name: remote ischemic preconditioning (RIPC); Assigned to Arm(s): remote ischemic preconditioning
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic preconditioning (RIPC) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SHAM | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning (RIPC); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: SHAM; Assigned to Arm(s): 2
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: donor; Type: EXPERIMENTAL; Interventions: Device: remote ischaemic preconditioning | Arm Label: recipient; Type: EXPERIMENTAL; Interventions: Device: remote ischaemic preconditioning | Intervention Type: DEVICE; Name: remote ischaemic preconditioning; Assigned to Arm(s): donor, recipient
D: Arm Label: Thrombolysis + Remote perconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Thrombolysis + remote perconditioning | Arm Label: Thrombolysis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Actilyse | Intervention Type: DRUG; Name: Actilyse; Assigned to Arm(s): Thrombolysis | Intervention Type: PROCEDURE; Name: Thrombolysis + remote perconditioning; Assigned to Arm(s): Thrombolysis + Remote perconditioning

Answer: A